Sources of variability on the estimate of treatment effect in the PROWESS trial: Implications for the design and conduct of future studies in severe sepsis

Critical Care Medicine

Volumn 32, Issue 12, 2004, Pages 2385-2391

  Macias, William L ^a   Vallet, Benoit ^b   Bernard, Gordon R ^c   Vincent, Jean Louis ^d   Laterre, Pierre Francois ^e   Nelson, David R ^a   Derchak, P Alexander ^f   Dhainaut, Jean Francois ^g  

^a ELI LILLY AND COMPANY   (United States)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ERASME HOSPITAL   (Belgium)

^e CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^f VivoMetrics Inc   (United States)

^g UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Activated protein C; Clinical trial; Drotrecogin alfa (activated); Protocol; Severe sepsis; Xigris

Indexed keywords

DROTRECOGIN; PLACEBO;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCORING SYSTEM; SEPSIS; TREATMENT OUTCOME; TREATMENT PLANNING;

ADULT; AGED; ANTI-INFECTIVE AGENTS; APACHE; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROTEIN C; RECOMBINANT PROTEINS; RISK ASSESSMENT; SEPSIS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 10644277923     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000147440.71142.AC     Document Type: Article

References (18)

1. Abraham E: Why immunomodulatory therapies have not worked in sepsis. Intensive Care Med 1999; 25:556-566
2. Chaudry IH: Sepsis: Lessons learned in the last century and future directions. Arch Surg 1999; 134:922-929
3. Dhainaut JF, Marin N, Cariou A. Perspectives in anti-inflammatory therapies in sepsis. Evolving concepts in sepsis and septic shock. Boston, MA, Kluwer Academic, 2001
4. Llewelyn M, Cohen J: Anti-endotoxin anti-bodies in sepsis: A critical evaluation. Sepsis 1999; 3:39-45
5. Sevransky JE, Natanson C: An analysis of clinical trials of mediator-specific anti-inflammatory agents. Sepsis 1999; 3:11-19
6. Wheeler AP, Bernard GR: Treating patients with severe sepsis. N Engl J Med 1999; 340:207-214
7. Sprung CL, Finch RG, Thijs LG, et al: International sepsis trial (INTERSEPT): Role and impact of a clinical evaluation committee. Crit Care Med 1996; 24:1441-1447
8. Dhainaut JF, Tenaillon A, Hemmer M, et al: Confirmatory platelet-activating factor receptor antagonist trial in patients with severe Gram-negative bacterial sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group. Crit Care Med 1998; 26:1963-1971
9. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
10. Dhainaut JF, Laterre PF, LaRosa SP, et al: The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): Role, methodology, and results. Crit Care Med 2003; 31:2291-2301
11. Breslow NE, Day NE. Statistical methods in cancer research. Volume I. The analysis of case-control studies. IARC Sci Publ 1980; 5-338
12. Pan G, Wolfe DA: Test for qualitative interaction of clinical significance. Stat Med 1997; 16:1645-1652
13. Ely EW, Laterre PF, Angus DC, et al: Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 2003; 31:12-19
14. Knaus WA, Draper EA, Wagner DP, et al: APACHE II: A severity of disease classification system. Crit Care Med 1985; 13:818-829
15. Graf J, Doig GS, Cook DJ, et al: Randomized, controlled clinical trials in sepsis: Has methodological quality improved over time? Crit Care Med 2002; 30:461-472
16. Sackett DL: Why randomized controlled trials fail but needn't: 1. Failure to gain "coal-face" commitment and to use the uncertainty principle. CMAJ 2000; 162:1311-1314
17. Vincent JL, Levy MM, Macias WL, et al: Early intervention with drotrecogin alfa (activated) improves survival benefit. Crit Care Med 2004; 31(Suppl):A123
18. Abraham E, Reinhart K, Opal S, et al: Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: A randomized controlled trial. JAMA 2003; 290:238-247